Generon commences F-627 Phase II trial in breast cancer

[News]

Generon Corporation Ltd. today announced the initiation of a Phase II clinical trial for F-627 after US FDA regulatory clearance. The current study is a Phase II, randomized, multicenter, open-label, active-controlled trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy.

More... (http://www.news-medical.net/news/20120504/Generon-commences-F-627-Phase-II-trial-in-breast-cancer.aspx)